PubMed

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG.

Diabetes Care. 2002 Apr;25(4):724-30.PMID: 11919132 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG.

Diabetes Care. 2003 Mar;26(3):784-90.PMID: 12610038 [PubMed - indexed for MEDLINE]Related articlesFree article

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG.

Diabet Med. 2004 Nov;21(11):1204-12.PMID: 15498087 [PubMed - indexed for MEDLINE]Related articles

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.

Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG.

Diabetes Technol Ther. 2002;4(1):51-61.PMID: 12017421 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.

Maggs D, Shen L, Strobel S, Brown D, Kolterman O, Weyer C.

Metabolism. 2003 Dec;52(12):1638-42.PMID: 14669170 [PubMed - indexed for MEDLINE]Related articles

Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets.

Ratner R, Whitehouse F, Fineman MS, Strobel S, Shen L, Maggs DG, Kolterman OG, Weyer C.

Exp Clin Endocrinol Diabetes. 2005 Apr;113(4):199-204.PMID: 15891954 [PubMed - indexed for MEDLINE]Related articles

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.

Singh-Franco D, Robles G, Gazze D.

Clin Ther. 2007 Apr;29(4):535-62. Review.PMID: 17617279 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

Edelman S, Garg S, Frias J, Maggs D, Wang Y, Zhang B, Strobel S, Lutz K, Kolterman O.

Diabetes Care. 2006 Oct;29(10):2189-95.PMID: 17003291 [PubMed - indexed for MEDLINE]Related articlesFree article

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group.

Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG.

Diabetes Care. 1998 Jun;21(6):987-93.PMID: 9614619 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes.

Wysham C, Lush C, Zhang B, Maier H, Wilhelm K.

Curr Med Res Opin. 2008 Jan;24(1):79-85.PMID: 18031595 [PubMed - indexed for MEDLINE]Related articles

Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.

Hollander P, Maggs DG, Ruggles JA, Fineman M, Shen L, Kolterman OG, Weyer C.

Obes Res. 2004 Apr;12(4):661-8.PMID: 15090634 [PubMed - indexed for MEDLINE]Related articles

Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.

Riddle M, Frias J, Zhang B, Maier H, Brown C, Lutz K, Kolterman O.

Diabetes Care. 2007 Nov;30(11):2794-9. Epub 2007 Aug 13.PMID: 17698615 [PubMed - indexed for MEDLINE]Related articlesFree article

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.

Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME.

Clin Ther. 2007 Jan;29(1):139-53.PMID: 17379054 [PubMed - indexed for MEDLINE]Related articles

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.

Clin Ther. 2007 Nov;29(11):2333-48.PMID: 18158075 [PubMed - indexed for MEDLINE]Related articles

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.

Buse JB, Rubin CJ, Frederich R, Viraswami-Appanna K, Lin KC, Montoro R, Shockey G, Davidson JA.

Clin Ther. 2005 Aug;27(8):1181-95.PMID: 16199244 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Aronne L, Fujioka K, Aroda V, Chen K, Halseth A, Kesty NC, Burns C, Lush CW, Weyer C.

J Clin Endocrinol Metab. 2007 Aug;92(8):2977-83. Epub 2007 May 15.PMID: 17504894 [PubMed - indexed for MEDLINE]Related articlesFree article

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.

Ryan GJ, Jobe LJ, Martin R.

Clin Ther. 2005 Oct;27(10):1500-12. Review.PMID: 16330288 [PubMed - indexed for MEDLINE]Related articles